Cobalis Reports Phase III Trial Results for PreHistin in Seasonal
IRVINE, Calif.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp.
(OTCBB:CLSC), a pharmaceutical development company specializing in
anti-allergy medications, today reported preliminary top-line
results from two Phase III clinical trials for its drug
PreHistin(TM) in patients with moderate to moderately...
Cobalis Expects to Report Phase III Top-Line Results in May
...igraine headache, atopic asthma and
dermatitis. Its flagship drug candidate prehistin
is an allergy
medication in Phase III clinical development. Cobalis plans to seek
FDA approval to market prehistin
over-the-counter in the US. For
further information, visit www.cobalis.com ...